Home > Archive>Volume 9, Issue 10, 2016 >1444-1450. DOI:10.18240/ijo.2016.10.13
HTML XML Export Cite reminder
Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy
Author:
Corresponding Author:

Yi Shao. Department of Ophthalmology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China. Freebee99@163.com

Fund Project:

Supported by National Natural Science Foundation of China (No.81160118; No.81400372; No.81660158); Jiangxi Province Voyage Project (No.2014022); Youth Science Foundation of Jiangxi Province (No.20151BAB215016); Technology and Science Foundation of Jiangxi Province (No.20151BBG70223); Health Development Planning Commission Science Foundation of Jiangxi Province (No.20155154).

  • Article
    • | |
  • Metrics
    • |
  • Reference
    • |
  • Related
    • |
  • Cited by
    • | |
  • Comments
    Abstract:

    AIM: To compare the effectiveness of combined fenofibrate and spironolactone with fenofibrate alone for treatment of central serous chorioretinopathy (CSCR). METHODS: Totally 60 patients (60 eyes) with a history of acute CSCR were randomed into two groups: group A with combination of fenofibrate (200 mg) and spironolactone (100 mg), and group B with only fenofibrate (200 mg). They were taken half an hour before meals and once per day for 8wk. The changes of the visual acuity, subjective symptom, ocular surface disease index (OSDI), the tear film and optical coherence tomography were observed at 2, 4, 6, and 8wk before and after treatment. RESULTS: The best corrected visual acuity (BCVA, logMAR) was improved to 0.22 and 0.27 after treatment from baseline of 0.35 and 0.36 in groups A and B (P<0.05), respectively. After 8wk treatment, the central subfield thickness (CST), and subretinal fluid volumn (SFV) decreased significantly to 49.5% and 78.8% in group A and 37.0% and 57.2% in group B. There were significant differences of CST and SFV in both groups (all P<0.05). CONCLUSION: Fenofibrate combined with spironolactone may have more clinical efficacy in the treatment of CSCR than fenofibrate only.

    Reference
    Related
    Cited by
Get Citation

Yong Chai, Rong-Qiang Liu, Jing-Lin Yi,/et al.Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy. Int J Ophthalmol, 2016,9(10):1444-1450

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:November 23,2015
  • Revised:April 13,2016
  • Online: October 13,2016
You are the  Visitors
Governing Body：Department of Health, Provincial Government of Shaanxi, China
Organizer：Xi'an Medical Association of China
Address：Room 11707-08, Building 2, Unit 1, Wanda Plaza, No.8 Yanta North Road, Xi'an 710054, Shaanxi Province, China
Fax：(8629)82245172 Phone：(+8629)82245172/82210956
Email：ijopress@163.com
International Journal of Ophthalmology ® 2025 All Rights Reserved   The terms of CC BY-NC-ND 4.0 are applicable to all open access content.